The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients

Taichung Tzu Chi Hospital120 enrolled

Overview

Gastroesophageal reflux disease(GERD) mainly related to the reflux of stomach content induced by the dysfunction of lower esophageal sphincter. Proton pump inhibitors (PPI) can effectively block gastric acid secretion but the drug reactions and the degree of improvement in symptoms are sometimes unpredictable. The aim of this study is to investigate the association between the clinical efficacy of PPI in patients with GERD and the personal physical status by Ryodoraku and ANSWatch.

Gastroesophageal reflux disease(GERD) is a common disease, mainly related to the reflux of stomach content induced by the dysfunction of lower esophageal sphincter. The common symptoms of GERD are heartburn, acid regurgitation, chest pain and globus hystericus. The methods to treat GERD are changes of lifestyle, pharmacotherapy, antireflux surgery and endoscopy. Proton pump inhibitors (PPI) can effectively block gastric acid secretion and promote the repair of esophagus, but the drug reactions and the degree of improvement in symptoms are sometimes unpredictable. Recently there are many instruments used to analyze personal physical status. Meridian energy analysis device ( Ryodoraku ) is used to assess the energy of meridian system by analysis of resistance of the skin surface, as well as the wrist-worn heart rate monitor (ANSWatch) used to assess the autonomic nervous system by analysis of heart rate variability. Therefore, the aim of this study is to investigate the association between the clinical efficacy of PPI in patients with GERD and the personal physical status by Ryodoraku and ANSWatch. Investigators will recruit 120 patients with GERD in clinic who have to receive PPIs for four weeks and assess each volunteer before and after taking the medication. Assessment methods : 1. ANSWatch to assess the autonomic nervous system, 2. Ryodoraku to assess the energy of meridian system, 3. Upper gastrointestinal endoscopy to assess the grade of reflux esophagitis, 4. gastroesophageal reflux disease questionnaire to assess the severity of GERD. Investigators analysed and compared the database from the assessments between before and after taking the medication. Investigators anticipate to substantiate that the changes of Ryodoraku and ANSWatch are good predictors for the clinical efficacy of PPI in patients with GERD.

Study Type

INTERVENTIONAL

Allocation

Purpose

Conditions

Non-erosive Reflux Disease Barrett's Esophagus

Interventions

RyodorakuDEVICE

Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication

ANSWatchDEVICE

ANSWatch to assess the autonomic nervous system for each patient before and after taking the medication

UGI endoscopyDEVICE

UGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication

Eligibility

Sex: ALLMin age: 20 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * male or female * age of 20-75 years * patients with GERD who have to receive PPIs for four weeks Exclusion Criteria: * Suffering from peptic ulcer, gallstones, cancer, and Barrett's esophagus * previously underwent the esophagus, stomach or duodenum surgery * Lactating women or pregnant women

Locations (1)

Taichung Tzu Chi Hospital

Taichung, Taiwan, Taiwan

Outcomes

Primary Outcomes

gastroesophageal reflux disease questionnaire

To assess the severity of GERD

Time frame: four weeks

Secondary Outcomes

Upper gastrointestinal endoscopy

To assess the grade of reflux esophagitis

Time frame: four weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.